{"id":"W3139163066","doi":"10.1200/jco.20.02619","title":"Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Placebo; Internal medicine; Adverse effect; Myelodysplastic syndromes; Anemia; Gastroenterology; Clinical endpoint; International Prognostic Scoring System; Azacitidine; Interim analysis; Randomized controlled trial; Surgery; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.01191203,0.0002738978,0.007421682,0.0004196165,0.00003839194,0.00001290322,0.0002640146,0.0005747553,0.0003713543],"category_scores_gemma":[0.04692469,0.000166838,0.001242811,0.000427647,0.000664759,0.0001579523,0.0001033472,0.002447526,0.00001449129],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003833876,"about_ca_system_score_gemma":0.006593064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002415295,"about_ca_topic_score_gemma":0.00004058713,"domain_scores_codex":[0.989515,0.003422619,0.005111741,0.0003399089,0.001135459,0.0004752537],"domain_scores_gemma":[0.9755242,0.01811111,0.003802823,0.0003624952,0.00161081,0.0005885954],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.937363,0.03648713,0.004766182,0.00003619451,0.001905456,0.0031832,0.00005592065,0.00002110134,0.000009566622,0.00003055385,0.001215623,0.01492608],"study_design_scores_gemma":[0.9394658,0.05433955,0.001950959,0.0002333898,0.001659022,0.0002079513,0.00006665124,0.0007383491,0.00002575106,0.0001166536,0.001058948,0.0001369932],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919133,0.0001748811,0.0003674565,0.002277383,0.001528847,0.002204159,0.000009568271,0.000007807979,0.00151664],"genre_scores_gemma":[0.9950607,0.0005836928,0.002392396,0.0004039499,0.00075843,0.00004207153,0.00001127944,0.00003337727,0.0007140363],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03501266,"threshold_uncertainty_score":0.9998538,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05024886019407585,"score_gpt":0.4222112638362222,"score_spread":0.3719624036421463,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}